The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.

[2] Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec.

In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration.

Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.

[6] Effective April 1, 2022 Paul Stoffels replaced cofounder and CEO of 20 years Onno van de Stolpe.